Today: 10 June 2026
Browse Category

NASDAQ:CCXIU 24 December 2025

Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next

Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next

Churchill Capital Corp X (NASDAQ: CCCX) surged nearly 10% to $17.27 on Dec. 23, 2025, and traded above $18 pre-market after Infleqtion’s chief scientist won the John Stewart Bell Prize. The rally is linked to renewed momentum around CCCX’s planned merger with Infleqtion, a quantum technology firm. CCCX remains a SPAC, with trading driven by sentiment and headlines.
24 December 2025
···

Stock Market Today

  • Northamber PLC Buys Back 200,000 Shares at 25p Each
    June 10, 2026, 9:06 AM EDT. Northamber PLC (AIM: NAR), a value-add Audio Visual and IT distributor, announced the purchase of 200,000 ordinary shares at 25 pence per share. These shares are to be issued to a consultant in exchange for services provided. Post-transaction, Northamber's total issued share capital will be 27,413,404 shares, with 27,113,404 carrying voting rights after accounting for 300,000 shares held in treasury. This transaction is disclosed under the UK's Market Abuse Regulation and relevant transparency rules. The shares were bought on the AIM market at 16:21:24. Investors can use the updated total share count to assess their shareholdings for regulatory notification requirements.

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
Go toTop